BS_BJDNWMJH
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- overall_survival_months
- 1.56
- os_event
- false
- age_years
- 18.321
- sex
- M
- race
- White
- e1_e2
- E2
- umap1_2d
- -8.801281845
- umap2_2d
- 0.288423093
- umap1_3d
- 0.174877904
- umap2_3d
- 2.823048781
- umap3_3d
- 2.670733366
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.600
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- MYC_TARGETS_V2+0.340
- DNA_REPAIR+0.320
- ADIPOGENESIS+0.300
- FATTY_ACID_METABOLISM+0.280
- GLYCOLYSIS+0.200
- TGF_BETA_SIGNALING+0.160
- PROTEIN_SECRETION+0.150
- MYC_TARGETS_V1+0.140
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.320
- INTERFERON_GAMMA_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.270
- ALLOGRAFT_REJECTION-0.250
- IL6_JAK_STAT3_SIGNALING-0.250
- COMPLEMENT-0.230
- G2M_CHECKPOINT-0.220
- SPERMATOGENESIS-0.220
- INTERFERON_ALPHA_RESPONSE-0.210
- KRAS_SIGNALING_DN-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_BJDNWMJH | Spinal Cord Ependymoma | — | 0.951 |
| 2 | MNG659 | — | — | 0.795 |
| 3 | BS_TBWYAFSM | Spinal Cord Ependymoma | — | 0.788 |
| 4 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.781 |
| 5 | R277 | — | — | 0.774 |
| 6 | MNG1094 | — | — | 0.766 |
| 7 | BS_TBWYAFSM | EPN | EPN Tumor | 0.764 |
| 8 | SRR6013593 | — | cohortA1 | 0.760 |
| 9 | e84aa97b-e429-4994-acef-2b57be71fe9a | — | — | 0.758 |
| 10 | 85094fa3-e9f3-4cab-8a1d-37cb0462404d | — | — | 0.749 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |